T‐025 strongly suppressed growth of the allograft tumors (Fig 7A) without inducing body weight losses (Fig 7B), suggesting that CLK inhibitors could exert anti‐tumor effects against MYC‐driven breast cancers. This evidence concerns the gene CLK1 and breast carcinoma.